Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Two common "forever chemicals" — PFOA and PFOS — are associated with up to 93% higher rates of estrogen receptor-negative (ER–) breast cancer, one of the most aggressive forms of the disease. A large NIH-backed prospective study published in the Journal of Clinical Oncology analyzed blood samples from over 3,800 women, finding no link to overall breast cancer but a striking connection to ER– tumors specifically.
Two widely encountered "forever chemicals" have been linked to significantly higher rates of an aggressive form of breast cancer, according to a major NIH-backed study published in the Journal of Clinical Oncology. Researchers analyzed blood samples from participants in the Sister Study — a prospective cohort of over 50,000 women — and found that higher blood levels of perfluorooctanoic acid (PFOA) and perfluorooctanesulfonic acid (PFOS) were associated with elevated risk of estrogen receptor-negative (ER–) breast cancer, a particularly aggressive subtype with few known risk factors.
Importantly, no link was found between these chemicals and overall breast cancer risk or ER-positive tumors. The findings suggest PFAS may act through non-hormonal mechanisms — such as epigenetic changes or immune suppression — rather than by mimicking estrogen. A supporting meta-analysis of seven studies further confirmed the PFOA–ER– breast cancer association.
By the Numbers:
Why it matters: ER– breast cancers are more aggressive and harder to treat than hormone receptor-positive tumors, yet their risk factors remain poorly understood. These findings open new avenues for prevention — and since PFAS exposure is potentially modifiable (e.g., through filtered water), they carry real public health weight.
